Golf, I don't disagree, although the trial states that IE was only administered for 18 months. So even though the entire study spanned 6 years, I am wondering if enrollment was staggered (ie. not all participants began administration at same time).
"Hopefully Ziploc is correct and the fda approves the use of vascepa for Alzheimer’s "
Approval for CVD seems to have little or no advantage for us. Why would Alzheimer be any different? Off label is off label. Seems to me the run on IPE and the impact on supply chain will only hurt us.